Axa S.A. Boosts Stock Holdings in Edwards Lifesciences Corporation $EW

Axa S.A. increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 11.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 716,907 shares of the medical research company’s stock after acquiring an additional 71,796 shares during the period. Axa S.A. owned about 0.12% of Edwards Lifesciences worth $56,069,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences in the second quarter worth $28,000. Quantbot Technologies LP purchased a new position in Edwards Lifesciences in the 1st quarter worth about $26,000. NewSquare Capital LLC raised its position in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the last quarter. SouthState Corp bought a new position in Edwards Lifesciences during the 1st quarter valued at about $27,000. Finally, Atlantic Union Bankshares Corp purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $40,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on EW shares. Stifel Nicolaus set a $100.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Friday. The Goldman Sachs Group set a $104.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a report on Friday, October 31st. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target on the stock in a research note on Monday, November 3rd. Barclays reiterated an “overweight” rating and set a $103.00 price objective (up previously from $99.00) on shares of Edwards Lifesciences in a research report on Monday. Finally, Canaccord Genuity Group set a $89.00 target price on Edwards Lifesciences in a report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $93.09.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 21,720 shares of company stock valued at $1,814,660. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $83.18 on Wednesday. The business has a 50-day simple moving average of $81.19 and a two-hundred day simple moving average of $78.88. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The stock has a market cap of $48.27 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 3.79 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.